TMD outcomes
| . | All patients . | Observation patients . | Intervention patients . | Observation vs intervention, P . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | 3-year % . | ± 2 SE% . | n . | 3-year % . | ± 2 SE% . | n . | 3-year % . | ± 2 SE% . | ||
| OS from study entry | 135 | 77 | 8 | 106 | 84 | 8 | 29 | 51 | 19 | < .001 |
| EFS from study entry | 135 | 57 | 10 | 106 | 64 | 11 | 29 | 33 | 18 | < .001 |
| mEFS from study entry | 135 | 68 | 9 | 106 | 76 | 10 | 29 | 36 | 18 | < .001 |
| LFS (from resolution) for patients whose TMD resolved | 107 | 80 | 9 | 92 | 78 | 10 | 15 | 71 | 25 | .327 |
| . | All patients . | Observation patients . | Intervention patients . | Observation vs intervention, P . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | 3-year % . | ± 2 SE% . | n . | 3-year % . | ± 2 SE% . | n . | 3-year % . | ± 2 SE% . | ||
| OS from study entry | 135 | 77 | 8 | 106 | 84 | 8 | 29 | 51 | 19 | < .001 |
| EFS from study entry | 135 | 57 | 10 | 106 | 64 | 11 | 29 | 33 | 18 | < .001 |
| mEFS from study entry | 135 | 68 | 9 | 106 | 76 | 10 | 29 | 36 | 18 | < .001 |
| LFS (from resolution) for patients whose TMD resolved | 107 | 80 | 9 | 92 | 78 | 10 | 15 | 71 | 25 | .327 |
EFS indicates event-free survival; LFS, leukemia-free survival; mEFS, modified event-free survival; and TMD, transient myeloproliferative disorder